Connect:        


All Releases
View Summary Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, and files an IND for Rexista(TM) Oxycodone XR
Mar 30, 2015
PDF 20.5 KB Add to Briefcase
View Summary Intellipharmaceutics Announces 2014 Year End Results With a 48% Reduction in Operating Loss
Feb 23, 2015
PDF 35.5 KB Add to Briefcase
View Summary Intellipharmaceutics Reports the Signing of an Exclusive Licensing and Manufacturing Agreement With Teva Pharmaceuticals USA, Inc. for an Extended Release Oral Drug Product Candidate
Feb 2, 2015
PDF 16.4 KB Add to Briefcase
View Summary Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva
Nov 20, 2014
PDF 18.0 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Appointment of New Chief Financial Officer
Nov 18, 2014
PDF 16.7 KB Add to Briefcase
View Summary Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification
Oct 27, 2014
PDF 17.0 KB Add to Briefcase
View Summary Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)
Oct 22, 2014
PDF 19.9 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Third Quarter 2014 Results
Oct 15, 2014
PDF 34.4 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Resignation of Chief Financial Officer
Sep 30, 2014
PDF 16.3 KB Add to Briefcase
View Summary Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology
Aug 28, 2014
PDF 19.9 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Second Quarter 2014 Results
Jul 7, 2014
PDF 32.9 KB Add to Briefcase
View Summary Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement
May 20, 2014
PDF 16.7 KB Add to Briefcase
View Summary Intellipharmaceutics Announces First Quarter 2014 Results
Apr 14, 2014
PDF 29.2 KB Add to Briefcase
View Summary Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
Mar 19, 2014
PDF 16.5 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at Two Upcoming Investor Conferences
Mar 4, 2014
PDF 16.8 KB Add to Briefcase
View Summary Intellipharmaceutics Announces 2013 Year End Results
Feb 18, 2014
PDF 31.7 KB Add to Briefcase
View Summary Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
Feb 3, 2014
PDF 16.5 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Dec 2, 2013
PDF 16.0 KB Add to Briefcase
View Summary Intellipharmaceutics Announces At-The-Market Offering of Common Shares
Nov 27, 2013
PDF 17.2 KB Add to Briefcase
View Summary Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R)
Nov 18, 2013
PDF 16.3 KB Add to Briefcase
Showing 61-80 of 159 Page: 1 2 3 4 5 6 ... 8  Previous 20 | Next 20
=add release to Briefcase